Major Depressive Disorder - Initial Pharmacotherapy

Key Points

• Confirm MDD and assess severity, function, suicide risk, psychosis, and catatonia before routine treatment.
• Screen for prior mania or hypomania before prescribing antidepressant monotherapy.
• For uncomplicated MDD, choose psychotherapy, pharmacotherapy, or both through shared decision-making.
• Antidepressant selection is individualized to prior response, adverse effects, comorbidity, interactions, and patient preference.
• Assess adherence and tolerability before labeling a medication ineffective.
• An adequate medication trial generally requires therapeutic dosing for several weeks.
• Psychotic depression, catatonia, or severe suicidality may require urgent specialty care and ECT.
• Continue effective treatment beyond symptom remission to reduce relapse.

Algorithm

1. Confirm depressive syndrome, functional impairment, and duration; assess suicide risk and urgent severity features.
2. Exclude bipolar disorder, substance-induced depression, and clinically relevant medical mimics.
3. Discuss psychotherapy, medication, or combined treatment based on severity, prior response, preference, and access.
4. If using medication, select an agent based on comorbidity, adverse-effect priorities, interactions, and patient history.
5. Reassess early for adverse effects, adherence, activation, and suicide risk.
6. After an adequate therapeutic trial, determine remission, partial response, or nonresponse.
7. Optimize, switch, augment, or move to advanced treatments according to response and severity.
8. Continue relapse-prevention treatment and monitor for recurrence after remission.

Clinical Synopsis & Reasoning

Major depressive disorder is diagnosed by a sustained syndrome of depressed mood and/or loss of interest accompanied by cognitive, somatic, and behavioral symptoms that cause distress or functional impairment and are not better explained by a substance, medical condition, or bipolar disorder. Assess sleep, appetite, energy, concentration, psychomotor change, guilt or worthlessness, anhedonia, and suicidal thoughts. Determine severity, duration, recurrence, psychotic features, catatonia, seasonal pattern, postpartum timing, substance use, trauma, and functional impact.

Screen carefully for past mania or hypomania before starting antidepressant monotherapy. Ask about periods of decreased need for sleep, elevated or markedly irritable mood, increased energy, pressured speech, racing thoughts, impulsive spending or sexual behavior, and episodes noticed by family or causing major consequences. A family history of bipolar disorder, antidepressant-induced activation, early recurrent depression, or episodic course raises suspicion but does not by itself establish bipolar diagnosis.

Medical testing is targeted. TSH is reasonable when thyroid disease is plausible; CBC, metabolic testing, B12, pregnancy testing, sleep evaluation, or other studies are selected according to symptoms and risk. Routine broad testing is unnecessary in a classic presentation without medical clues. Assess suicide risk at the initial visit and whenever symptoms worsen. Psychotic depression, severe inability to eat or drink, catatonia, imminent suicide risk, or inability to function safely requires urgent specialty evaluation and may warrant hospitalization or ECT rather than routine outpatient medication titration.

Treatment Strategy & Disposition

For uncomplicated MDD, current VA/DoD guidance supports selecting evidence-based psychotherapy, pharmacotherapy, or both through shared decision-making. Medication choice is usually driven more by adverse-effect profile, comorbidity, prior response, interactions, cost, and patient preference than by large differences in average antidepressant efficacy. SSRIs such as sertraline, escitalopram, or fluoxetine are common first choices. SNRIs can be useful when neuropathic pain is also present. Bupropion is less likely to cause sexual dysfunction or weight gain but can worsen anxiety in some patients and is contraindicated in seizure disorders and eating disorders that increase seizure risk. Mirtazapine can help when insomnia and poor appetite are prominent but often causes sedation and weight gain.

Explain that improvement is gradual. Some adverse effects appear before mood benefit. Reassess early for tolerability and suicide risk and assess response after an adequate therapeutic trial, often four to six weeks at a therapeutic dose before declaring nonresponse, while recognizing that some patients need longer. If there is partial response, optimize dose, adherence, and psychotherapy before switching or augmenting. If there is no meaningful response despite adequate adherence, switch antidepressant or treatment modality. More resistant illness may require augmentation, rTMS, ketamine/esketamine, ECT, or specialty management.

Continue effective treatment after remission to reduce relapse, generally for at least several months and longer after recurrent, severe, chronic, psychotic, or high-risk episodes. Taper medications with discontinuation risk rather than stopping abruptly. Integrate sleep, exercise, substance-use treatment, social support, and management of comorbid anxiety or pain. Psychotherapy remains effective alone or combined with medication and should be offered according to access and preference.

Epidemiology / Risk Factors

• MDD is common across the lifespan and is a major cause of disability.
• Recurrence risk increases with the number of prior episodes, residual symptoms, chronicity, and severe psychosocial stress.
• Anxiety, substance use, chronic pain, insomnia, and medical illness commonly coexist and affect treatment response.
• Suicide risk varies over time and should be reassessed during clinical worsening and treatment transitions.

Investigations

Choice Clues

Pharmacology

Prognosis / Complications

• Many patients respond to an initial evidence-based psychotherapy or antidepressant, but full remission may require treatment adjustment.
• Residual symptoms predict relapse and should be treated rather than accepted as the best achievable outcome without discussion.
• Continuation treatment after remission reduces relapse risk.
• Recurrent or treatment-resistant depression can still respond to augmentation, neuromodulation, or ECT.

Patient Education / Counseling

• Explain expected onset, common adverse effects, and what symptoms should prompt earlier contact rather than simply handing the patient a prescription.
• Do not stop an antidepressant abruptly without a taper plan unless an urgent adverse reaction requires immediate action.
• Report new marked agitation, decreased need for sleep, unusually elevated mood, or risky behavior because these may indicate bipolar activation.
• Psychotherapy and medication are both evidence-based; treatment choice should reflect preference and severity.
• Continue medication through the recommended maintenance period even after feeling better unless the treatment plan is deliberately changed.

Notes

Initial antidepressant choice is often presented as if one medication is universally best. In reality, average efficacy differences among common first-line agents are modest, while side effects and comorbidity differ substantially. Asking what adverse effect the patient most wants to avoid can be as useful as choosing among medication classes.

Measurement-based care improves decision-making when symptom scores are interpreted alongside function and patient goals. A lower PHQ-9 with continued inability to work, care for family, or experience pleasure may still represent inadequate response. The target is meaningful remission, not merely statistical improvement.

Before escalating medications, check whether the original diagnosis still fits. Unrecognized bipolar disorder, alcohol or stimulant use, sleep apnea, severe trauma symptoms, thyroid disease, medication nonadherence, and psychosocial instability can all make apparent “treatment-resistant depression” a different clinical problem.

References

1. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022) — Link
2. APA Practice Guideline Resources — Link
3. FDA Antidepressant Medication Guides and Safety Information — Link